Last week, the U.S. Food and Drug Administration (FDA) approved the first generic version of liraglutide injection, a game-changing development that promises to improve patient access to life ...

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of ...

Only 34 of 79 websites stated that compounded drugs were not FDA approved; 39 websites did not report adverse effects, warnings.

Liraglutide has been in shortage in the US since July 2023, according to an FDA database. The agency, in its Monday announcement, noted it “prioritizes assessment of generic drug applications ...

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who are 10 years old and up with Type 2 diabetes. The liraglutide ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

The generic liraglutide includes a Boxed Warning to advise ... dyspepsia and constipation. “The FDA supports development of complex generic drugs, such as GLP-1s, by funding research and ...

The FDA approved the first generic in this class of medications last month with the approval of a generic referencing Byetta (exenatide). Liraglutide injection and certain other GLP-1 medications ...

According to the Company, the generic product will launch immediately. The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ®.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...